Table 1.
Control Group (n=11) | VR-JIT Group (n=21) | p-value | |
---|---|---|---|
Demographics | |||
Age, mean years (SD) | 39.1 (10.6) | 40.8 (12.2) | 0.76 |
Gender (% male) | 54.5% | 52.4% | 0.34 |
Parental education, mean years (SD) | 11.7 (1.8) | 12.9 (3.4) | 0.46 |
Race | |||
% Caucasian | 27.3% | 28.6% | |
% African-American | 54.5% | 66.7% | 0.29 |
% Latino | 18.2% | 4.8% | |
Vocational history | |||
Months since prior employment, mean (SD)a | 26.9 (41.0) | 65.2 (92.4) | 0.27 |
Prior full-time employment (%) | 63.6% | 71.4% | 0.87 |
Prior paid employment (any type) (%) | 100% | 95.2% | 0.53 |
Prior participation in vocational training program | 27.3% | 38.1% | 0.37 |
Cognitive function | |||
Neurocognition, mean (SD) | 72.5 (12.6) | 74.8 (16.4) | 0.76 |
Basic social cognition, mean (SD) | 0.71 (0.2) | 0.69 (0.1) | 0.67 |
Advanced social cognition, mean (SD) | 0.77 (0.1) | 0.74 (0.1) | 0.88 |
Clinical history | |||
Duration of illness, mean years (SD) | 16.0 (11.4) | 19.5 (11.2) | 0.41 |
Clinical symptoms | |||
Hallucinations | 2.36 (2.1) | 1.71 (1.8) | 0.34 |
Delusions | 2.36 (2.1) | 2.50 (1.9) | 0.88 |
Bizarre behavior | 0.36 (0.8) | 0.95 (1.2) | 0.24 |
Thought disorder | 1.18 (1.3) | 0.90 (1.3) | 0.56 |
Affective flattening | 1.64 (1.4) | 1.86 (1.6) | 0.73 |
Alogia | 1.27 (1.3) | 1.14 (1.5) | 0.79 |
Avolitionb | 2.90 (0.8) | 2.90 (1.1) | 0.86 |
Anhedoniac | 2.38 (1.6) | 3.73 (1.4) | 0.05 |
Attentionc | 1.75 (0.9) | 2.00 (1.5) | 0.73 |
Chlorpromazine equivalent | 245.25 (164.9) | 340.81 (197.9) | 0.18 |
Treated with atypical antipsychotic medication | 81.8% | 90.0% | |
Treated with typical antipsychotic medication | 18.2% | 10.0% | 0.52 |
two outliers excluded for VR-JIT trainees: 324 months and 276 months;
one VR-JIT trainee was not rated on this domain;
three controls and six VR-JIT trainees were not rated on this domain